Litcius/Paper detail

Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies

Nicola Cotugno, Alessandra Ruggiero, Francesco Bonfante, Maria Raffaella Petrara, Sonia Zicari, Giuseppe Rubens Pascucci, Paola Zangari, Maria Antonietta De Ioris, Veronica Santilli, Emma Concetta Manno, Donato Amodio, Alessio Bortolami, Matteo Pagliari, Carlo Concato, Giulia Linardos, Andrea Campana, Daniele Donà, Carlo Giaquinto, Stefania Bernardi, Lorenza Romani, Paola Pansa, Sara Chiurchiù, Andrea Finocchi, Caterina Cancrini, Laura Lancella, Laura Cursi, Maia De Luca, Renato Cutrera, Libera Sessa, Francesca Rocchi, Chiara Medri, Lorenza Putignani, Francesca Ippolita Calò Carducci, Patrizia D’Argenio, Marta Luisa Ciofi degli Atti, Carmen D’Amore, Livia Piccioni, Martina Di Giuseppe, Alessandro Jenkner, Carmela Giancotta, Andrzej Krzysztofiak, Petter Brodin, Paolo Rossi, Anita De Rossi, Paolo Palma

2021Cell Reports58 citationsDOIOpen Access PDF

Abstract

patients show higher viral signal transduction molecules (SLAMF1, CD244, CLEC4G). This work sheds lights on cellular and humoral anti-SARS-CoV-2 responses in children, which may drive future vaccination trial endpoints and quarantine measures policies.

Topics & Concepts

AntibodyVirologyImmunologyImmune systemNeutralizing antibodyHumoral immunityMedicineImmunityVaccinationViral loadInfectivitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyCoronavirus disease 2019 (COVID-19)VirusInfectious disease (medical specialty)DiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19